Balance confidence may not accurately assess fall risk in atypical parkinsonism
Objective: Objective: To examine if balance confidence, measured by the Activities-specific Balance Confidence (ABC) scale, reflects fall frequency in atypical parkinsonian syndromes (APS), namely multiple…White Matter Abnormalities in Progressive Supranuclear Palsy (PSP) vs. Parkinson’s Disease (PD): Evaluation with a Convolutional Neural Network (CNN)-Based Tool
Objective: This study aimed to compare white matter hyperintensity (WMH) burden between PSP and PD using a novel AI-based tool for more accurate WMH volume…Safety, Tolerability and Pharmacokinetics of a Novel Oral OGA Inhibitor (FNP-223) First-in-Human Phase 1 Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics of FNP-223 (formerly ASN90) in healthy volunteers (HV). Background: Proteinopathies remain largely untreatable and novel therapies are…Temporal disease patterns prior to Progressive Supranuclear Palsy diagnosis
Objective: To identify Progressive Supranuclear Palsy (PSP) disease trajectories, defined as the pattern of diagnoses over time, prior to PSP diagnosis in electronic health records.…Association between Imaging Glymphatic Dysfunction Markers and Clinical Symptoms in Progressive Supranuclear Palsy
Objective: This study aims to explore possible glymphatic dysfunction using diffusion tensor image analysis along the perivascular space (DTI-ALPS) in patients with progressive supranuclear palsy…Brain Target Engagement and Pharmacokinetic-Enzyme Occupancy (PK-EO) Relationship of FNP-223: A Novel Oral OGA Inhibitor for Progressive Supranuclear Palsy – Phase 1 PET Study
Objective: To determine the brain O-GlcNAcase (OGA) occupancy, following a single oral dose of FNP-223 (formerly ASN90) and to determine PK-EO relationship. Background: Preclinical evidence…Video-oculography for enhancing the diagnostic accuracy of early oculomotor dysfunction in Progressive Supranuclear Palsy
Objective: To test (1) the role of video oculography (VOG) in the detection of slow saccades in two common subtypes of Progressive Supranuclear Palsy (PSP)…Early Syndromes and Clinicopathologic Progression in Progressive Supranuclear Palsy
Objective: We aimed to characterize early clinical features of progressive supranuclear palsy (PSP) that might correlate with clinical course and neuropathologic findings. Background: Progressive supranuclear…Frontal atrophy in progressive supranuclear palsy[PSP] -an universal feature along with midbrain atrophy?
Objective: To see if frontal atrophy is a frequent radiologic feature of PSP on MRI imaging . Background: Progressive supranuclear palsy[PSP] is a taupathy that…Combined application of alpha-synuclein and 4-repeat tau seed amplification assays for the differential diagnosis of parkinsonian disorders
Objective: To assess alpha-synuclein (a-syn) and 4-repeat tau (4RT) seed amplification assay (SAA) positivity rates in biosamples from people with Parkinson’s disease (PD) and Progressive…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 42
- Next Page »